Gilead Sciences | GILD - Bruttoergebnis Vom Umsatz





Bruttoergebnis Vom Umsatz Veränderung Datum
AbbVie USD 14.39B 1.85B 2026-06
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
ALKERMES USD 375.31M 43.98M 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
Biogen USD 2.12B 307M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 16.22B 301.7M 2026-03
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Incyte USD 1.57B 400.89M 2026-06
J&J USD 18.55B 1.31B 2026-06
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Pfizer USD -248M 11.29B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.71B 602M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06